Alison Burman

Performance of prototype serological immunoassays for foot-and-mouth disease virus using G-H loop peptides and stabilized virus-like particles

Abdelaziz A. Yassin, Yvonne Sewell, Anna B. Ludi, Alison Burman et autres

ABSTRACT Inter-serotype cross-reactivity of foot-and-mouth disease (FMD) antibody enzyme-linked immunosorbent assays (ELISAs) can exceed 50%, leading to incorrect serotyping of outbreaks with implications for vaccine selection. In this study, synthetic peptides that mimic the hypervariable G-H loop of FMD viruses (FMDVs) that …

gb, Égypte, fr (code pays fourni par la source)

Cattle antibodies identify a cross-serotype broadly neutralising foot-and-mouth disease virus epitope

Marie Bonnet‐Di Placido, Helen M. E. Duyvesteyn, Angela W. Steyn, Abigail L. Hay et autres

Abstract Foot-and-mouth disease virus (FMDV) causes a devastating disease that threatens global food security. Vaccination is hindered by antigenic diversity across serotypes. To identify cross-serotype neutralising epitopes, we isolated 24 FMDV-specific antibodies from cattle sequentially vaccinated with antigens from four serotypes, of …

gb, ca, nl (code pays fourni par la source)

Conserved Linear Epitopes in the VP1 Protein of Foot‐and‐Mouth Disease Virus Serotype SAT2: Identification and Characterization

Yu-qian Zhu, Xin-tai Shi, Alison Burman, Zheng-wang Shi et autres

Foot‐and‐mouth disease virus (FMDV) serotype Southern African Territories 2 (SAT2), historically endemic to sub‐Saharan Africa, has recently expanded its geographical range to the Middle East, posing a significant transboundary threat to global livestock industries. Characterized by high genetic diversity encompassing 14 distinct …

cn, gb (code pays fourni par la source)

LOAD3: A new preclinical mouse model that incorporates humanized APOE4 , Aβ and MAPT

Gareth R. Howell, Dylan T. Garceau, Kevin P. Kotredes, Ravi S. Pandey et autres

BACKGROUND: The MODEL-AD (Model Organism Development and Evaluation for Late-Onset Alzheimer's Disease) Consortium is creating a new generation of mouse models for Alzheimer's disease (AD) based on genetic and environmental factors shown to increase risk for human AD. The IU/JAX/PITT MODEL-AD Center …

us (code pays fourni par la source)

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Kaja Abbas et autres

BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital …

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jonathan Raihan Abbas et autres

BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …

Foot-and-mouth disease vaccine quality: A universal test for intact viral capsids based on detection of VP4

Stephen Berryman, A. Asfor, Emily C. Benham, N Howe et autres

Foot-and-mouth disease virus (FMDV) causes an economically devastating disease of livestock that is controlled in endemic areas by vaccines containing intact inactivated FMDV particles. In this study, a novel monoclonal antibody named 5B6 has been identified and characterised, that permits the detection …

gb, it (code pays fourni par la source)

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jaffar Abbas et autres

Background: Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination of non-invasive …

237 Study of Peri-Resuscitation Troponin and Outcomes (SANTO) Proof of Concept

Graham Nichol, Barbara Ann Mullan, B. Okerman, Dryden P. Morse et autres

us (code pays fourni par la source)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter AG Sandercock, Janet H Darbyshire, David L. DeMets, Robert Fowler et autres

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In …

gb, us, ca (code pays fourni par la source)

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

Saul N. Faust, Richard Haynes, Christine Elizabeth Jones, Natalie Staplin et autres

BACKGROUND: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with …

us, de, gb (code pays fourni par la source)

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jonathan Raihan Abbas et autres

BACKGROUND: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19. METHODS: In the randomised, controlled, …